Pfizer Venture Investments (PVI) serves as the venture capital arm of Pfizer, supporting a variety of worldwide business development (WWBD) activities. Using Pfizer capital, they invest in innovative healthcare businesses offering new technology platforms that align with their company’s strategic direction. They actively support companies—both financially and as board representatives—as appropriate.
| Company | Date | Round | Size | Participants |
| Cydan | 4/13 | Venture Round | $16M | 3 |
| Aquinox Pharmaceuticals | 4/13 | Series C | $18M | 5 |
| Flexion Therapeutics | 12/12 | Series B | $20M | 5 |
| Rhythm Pharmaceuticals | 11/12 | Series B | $8M | 5 |
| Epic Sciences | 11/12 | Series B | $13M | 3 |
| Ziarco Pharma | 11/12 | Series A | $6M | 2 |
| Mirna Therapeutics | 10/12 | Series C | $34.5M | 5 |
| Mersana Therapeutics | 7/12 | Series A | $27M | 4 |
| Celladon | 2/12 | Venture Round | $43M | 6 |
| DVS Sciences | 7/11 | Series A | $14.6M | 3 |
| Neuronetics | 5/11 | Series E | $30M | 8 |
| TetraLogic Pharmaceuticals | 9/10 | Series C | $5M | 1 |
| Aquinox Pharmaceuticals | 6/10 | Series B | $25M | 4 |
| Ablexis | 6/10 | Series A | $12M | 2 |
| Nodality | 3/10 | Venture Round | $2M | 2 |
| Flexion Therapeutics | 1/10 | Series A | $9M | 1 |
| Avid Radiopharmaceuticals | 5/09 | Series D | $34.5M | 8 |
| HD Biosciences | 8/08 | Series A | 3 |
